FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Chard Daniel R
2. Issuer Name and Ticker or Trading Symbol

MEDIFAST INC [ MED ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)

10/3/2019
(Street)

BALTIMORE, MD 21202
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/3/2019    F    1847  D $101.25  18930  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Chard Daniel R
C/O MEDIFAST, INC.
100 INTERNATIONAL DRIVE, 18TH FLOOR
BALTIMORE, MD 21202
X
Chief Executive Officer

Signatures
/s/ Jason L. Groves, attorney-in-fact 10/4/2019
**Signature of Reporting Person Date


Grafico Azioni Medifast (NYSE:MED)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Medifast
Grafico Azioni Medifast (NYSE:MED)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Medifast

Notizie Medifast Inc - MED

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Medifast to Announce Financial Results for the First Quarter Ended March 31, 2024
Lunedì 15 Aprile 2024 (3 giorni fa) • Business Wire
Form 144 - Report of proposed sale of securities
Venerdì 8 Marzo 2024 (1 mese fa) • Edgar (US Regulatory)
Form 8-K - Current report
Martedì 20 Febbraio 2024 (2 mesi fa) • Edgar (US Regulatory)
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Martedì 20 Febbraio 2024 (2 mesi fa) • Edgar (US Regulatory)
Medifast Announces Fourth Quarter and Full Year 2023 Financial Results
Martedì 20 Febbraio 2024 (2 mesi fa) • Business Wire
Market Cautiousness Ahead of Retail Giants’ Earnings; Oil Prices Dip
Martedì 20 Febbraio 2024 (2 mesi fa) • IH Market News
Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 16 Febbraio 2024 (2 mesi fa) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 16 Febbraio 2024 (2 mesi fa) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Martedì 13 Febbraio 2024 (2 mesi fa) • Edgar (US Regulatory)
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2023
Martedì 6 Febbraio 2024 (2 mesi fa) • Business Wire
Form 8-K - Current report
Mercoledì 13 Dicembre 2023 (4 mesi fa) • Edgar (US Regulatory)
LifeMD and Medifast Partner to Offer Transformative Weight Management Solution
Mercoledì 13 Dicembre 2023 (4 mesi fa) • GlobeNewswire Inc.